Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study

被引:91
作者
Griesinger, G. [1 ]
von Otte, S. [1 ]
Schroer, A. [1 ]
Ludwig, A. K. [1 ]
Diedrich, K. [1 ]
Al-Hasani, S. [1 ]
Schultze-Mosgau, A. [1 ]
机构
[1] Med Univ Lubeck, Clin Schleswig Holstein, Dept Obstet & Gynecol, D-23538 Lubeck, Germany
关键词
frozen-thawed embryo replacement; GnRH agonist; GnRH antagonist; ovarian hyperstimulation syndrome;
D O I
10.1093/humrep/dem006
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
BACKGROUND: A bolus dose of GnRH agonist can substitute for hCG as a trigger for the resumption of meiosis in ovarian stimulation with GnRH antagonists, which has been suggested to reduce the risk of ovarian hyperstimulation syndrome (OHSS). As the efficacy of this measure in fresh embryo transfer (ET) cycles is unclear, we evaluated a new clinical concept of GnRH-agonist triggering. METHODS: In this prospective, observational proof-of-concept study, 20 patients considered at increased risk of developing OHSS (>= 20 follicles >= 10 mm or estradiol >= 4000 pg/ml, or a history of cycle cancellation due to OHSS risk or the development of severe OHSS in a previous cycle) after ovarian stimulation and concomitant GnRH-antagonist administration had final oocyte maturation triggered with 0.2 mg triptorelin s.c. All two pronucleate (2 PN) oocytes were cryopreserved by vitrification, and frozen-thawed ETs (FT-ETs) were performed in an artificial cycle. Main outcome measures were the cumulative ongoing pregnancy rate per patient and the ongoing pregnancy rate per first ET. Secondary outcomes included the incidence of moderate-to-severe OHSS. RESULTS: Of the 20 patients triggered with GnRH agonist, 19 patients underwent 24 FT-ETs in the observational period. The cumulative ongoing pregnancy rate was 36.8% (95% confidence interval: 19.1-59.0%). The ongoing pregnancy rate per first FT-ET was 31.6 % (15.4-54.0%). No cases of moderate or severe OHSS were observed. CONCLUSIONS: The present study is the proof of the concept that GnRH-agonist triggering of final oocyte maturation in combination with elective cryopreservation of 2 PN oocytes offers OHSS risk patients a good chance of pregnancy achievement, while reducing the risk of moderate and severe OHSS.
引用
收藏
页码:1348 / 1352
页数:5
相关论文
共 36 条
[1]  
ANDERSEN CY, 2005, HUM REPROD S1, V20, P65
[2]   Serum inhibin A, VEGF and TNFα levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment:: a prospective randomized trial [J].
Babayof, R ;
Margalioth, EJ ;
Huleihel, M ;
Amash, A ;
Zylber-Haran, E ;
Gal, M ;
Brooks, B ;
Mimoni, T ;
Eldar-Geva, T .
HUMAN REPRODUCTION, 2006, 21 (05) :1260-1265
[3]   A simple, inexpensive and effective artificial cycle with exogenous transdermal oestradiol and vaginal progesterone for the transfer of cryopreserved pronucleated human oocytes in women with normal cycles [J].
Bals-Pratsch, M ;
Al-Hasani, S ;
Schöpper, B ;
Diedrich, C ;
Hoepfner, AS ;
Weiss, J ;
Küpker, W ;
Felberbaum, R ;
Ortmann, O ;
Bauer, O ;
Diedrich, K .
HUMAN REPRODUCTION, 1999, 14 :222-230
[4]   Severe OHSS can be prevented in GnRH antagonist protocol using GnRH agonist to trigger ovulation. [J].
Chun, E .
FERTILITY AND STERILITY, 2005, 84 :S301-S301
[5]   Reproductive biology and IVF: ovarian stimulation and endometrial receptivity [J].
Devroey, P ;
Bourgain, C ;
Macklon, NS ;
Fauser, BCJM .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2004, 15 (02) :84-90
[6]  
*DTSCH IVF REG, 2004, ANN REP GERM IVF REG
[7]   Prevention of ovarian hyperstimulation syndrome (OHSS) with the use of gonadotropin releasing hormone (GnRH) agonist to trigger final oocyte maturation after cotreatment with GnRH antagonist in patients with polycystic ovarian syndrome (PCOS) or previous high response undergoing IVF treatment - A prospective randomized clinical trial. [J].
Engmann, L ;
Diluigi, A ;
Schmidt, D ;
Nulsen, J ;
Maier, D ;
Benadiva, C .
FERTILITY AND STERILITY, 2005, 84 :S96-S96
[8]   Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization [J].
Fauser, BC ;
de Jong, D ;
Olivennes, F ;
Wramsby, H ;
Tay, C ;
Itskovitz-Eldor, J ;
van Hooren, HG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (02) :709-715
[9]  
Golan A, 1989, Obstet Gynecol Surv, V44, P430, DOI 10.1097/00006254-198906000-00004
[10]   GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis [J].
Griesinger, G ;
Diedrich, K ;
Devroey, P ;
Kolibianakis, EM .
HUMAN REPRODUCTION UPDATE, 2006, 12 (02) :159-168